期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

卵巢癌过度化疗因素分析 被引量：1

Analysis of over chemotherapy for ovarian cancer
原文传递
导出
摘要 化疗是卵巢癌主要的辅助治疗手段。然而,卵巢癌的化疗在临床上仍存在治疗不当,特别是过度治疗的问题。文章旨在对卵巢癌治疗中引起过度化疗的原因作一分析探讨。 Chemotherapy is a crucial adjuvant therapy for epithelial ovarian cancer. However, there is some inappropriate application of chemotherapy in clinical treatment, especially overtreatment. This article aims to discuss the causes which leads to excessive chemotherapy in the cure of ovarian cancer.
作者 郝敏
机构地区 山西医科大学第二医院妇产科
出处 《中国实用妇科与产科杂志》 CAS CSCD 北大核心 2011年第7期491-495,共5页 Chinese Journal of Practical Gynecology and Obstetrics
关键词 卵巢癌 过度化疗 ovarian cancer excessive chemotherapy
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献19

  • 1Le T, Adolph A, Krepart GV, et al. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovari- an carcinoma [ J ]. Gynecol Onco1,2002,85 ( 2 ) : 351-355.
  • 2Sugiyama T, Yoshizaki A, Hatayama S. Influence of the gyneco-logic oneologist on the survival of ovarian cancer patients [ J ]. Ob- stet Gynecol,2007,109 (6) : 1342-1350.
  • 3Vergote I,Trop CG, Amant F, et al. EORTC-GCG/NCIC-CTG randomised trial comparing primary debulking surgery with neo- adjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer (OVCA) [ J ]. Society IGCS, 2008,10 : 25 -28.
  • 4Kang S, Nam BH. Does neoadjuvant chemotherapy increase opti- mal cytoredu-ction rate in advanced ovarian cancer? Meta-analy- sis of 21 studies [ J ]. Ann Surg Oncol, 2009,16 ( 8 ) :2315 -2320.
  • 5Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis [J]. Gynecol 0ncol,2006,103 ( 3 ) : 1070-1076.
  • 6Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage 1I epithelial ovarian cancer. Results of two prospective randomized trials [J]. N Engl J Med, 1990,322: 1021-1027.
  • 7Ozols RF, Bundy BN, Greer BE, et al. Phase m trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel inpatients- with optimally resected stagelllovarian cancer: a GynecologicOn- cologyGroup study[ J]. J Clin Oncol,2003, 21:3194-3200.
  • 8Pignata S, Scambia G, Savarese A, et al. Carboplatin and pegy- lated liposomal doxorubicin for advanced ovarian cancer: prelimi- nary activity results of the MITO-2 phase m tnl[J]. Oneology, 2009,76( 1 ) :49-54.
  • 9Bookman MA, Brady MF, McGuire WP,et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup [ J ]. J Clinical Onco1,2009,27 (9) : 1419-1425.
  • 10郎景和.卵巢上皮癌的化疗[M]//连利娟,主编.林巧稚妇科肿瘤学.2版.北京:人民卫生出版社,1994:542-545.

同被引文献12

  • 1李春荣.晚期卵巢恶性肿瘤理想细胞减灭术的可行性[J].海军总医院院刊,1994,7(4):236-239. 被引量：1
  • 2Arikan SK, Kasap B, Yetimalar Het al. Impact of prognostic factors on survival rates in pa!ients with ovarian carcinoma [J]. Asian Pac J Cancer Prey,2014,15(15):6087-6094.
  • 3Pereira A,Prrez-Medina T,Magrina JF,et al. Correlation between the extent of intraperitoneal disease and nodal metastasis in node-positive ovarian cancer patients[J]. Eur J Surg Oncal,2014,40(8):917-924.
  • 4Lin JE,Seo S,Kushner DM,et al.The role of appendecto- my for mucinous ovarian neoplasms [J]. Am J Obstet Gy- necol, 2013,208(1) : 46.e l-e4.
  • 5Fontanclli R,Paladini D,Raspagliesi F,et al.The role of appendectomy in surgical procedures for ovarian cancer[J]. Gynecol Oncol, 1992,46(1) :42-44.
  • 6Panici PB,Maggioni A, Hacker N,et al.Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian can- cer:a randomized clinical trial [J]. J Natl. Cancer Inst, 2005,97(8) : 560-566.
  • 7Berek JS. Lymph node positive stage ]]I C ovarian cancer a separate entity?[J].Int J Gynecol Cancer, 2009,19 :S 18-$20.
  • 8Chan JK,Manro EG,Cheung MK,et al. Association of lymphadenectomy and survival in stage I ovarian cancer patients[J]. Obstet Gyneco1,2007,109(1) : 12-19.
  • 9Aletti GD,Dowdy S,Podratz KC,et al. Role of lym- phadenectomy in the management of grossly apparent ad- vanced stage epithelial ovarian eancer[J].Am J Obstet Gy- necol, 2006, 195(6) : 1862-1868.
  • 10Tewari D,Java JJ,Salani R,et al. Long-term survival ad- vantage mad prognostic factors associated with intraperi- toneal chemotherapy treatment in advanced ovarian can- cer:a gynecologic oncology group study [J].J Clin Oncol, 2015,23 : 1000-1005.

引证文献1

二级引证文献6

中国实用妇科与产科杂志
2011年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部